抗肾病蛋白自身抗体的自动化化学发光免疫检测
该研究建立了检测抗肾病蛋白IgG的自动化化学发光免疫分析法(CLIA),在121例活检确诊的儿童微小病变(MCD)或原发性局灶节段性肾小球硬化(FSGS)患者及对照中验证,与免疫沉淀-免疫印迹(IP-WB)总体一致率86.8%(κ=0.714),CLIA检出阳性率更高(41.3% vs. 28.1%),抗体阳性与更重蛋白尿、更低白蛋白、激素敏感及更短无复发生存相关。
要点
- CLIA检测抗肾病蛋白IgG与IP-WB一致性86.8%(κ=0.714)。
- CLIA在MCD/FSGS中阳性率41.3%,高于IP-WB的28.1%。
- 完全缓解期抗体阳性与3个月内复发相关,风险随抗体水平升高。
核心结论
- 自动化CLIA可推动抗肾病蛋白IgG检测从专业研究流程向标准化临床应用转化,支持疾病分层和纵向监测。
研究设计与样本
- 研究采用重组人肾病蛋白胞外域包被磁性微粒建立自动化CLIA。
- 检测121例活检确诊的儿童MCD(n=103)或原发性FSGS(n=18)及疾病对照和健康人的血清抗肾病蛋白IgG。
- 样本平行用免疫沉淀-免疫印迹(IP-WB)检测,并进行抗原抑制试验和队列临床分析。
主要发现
- CLIA符合预设分析性能标准,与IP-WB总体一致率86.8%,Cohen's kappa系数0.714。
- CLIA在MCD或FSGS患者中检出抗肾病蛋白IgG的频率高于IP-WB(41.3% vs. 28.1%),包括额外低水平阳性样本。
- 抗原抑制试验显示CLIA阳性样本呈剂量依赖性抑制。
- 基线肾病范围蛋白尿患者中,抗体阳性与更重蛋白尿、更低血清白蛋白和激素敏感肾病综合征相关。
- 抗肾病蛋白IgG水平升高患者无复发生存期显著缩短;完全缓解期抗体阳性与3个月内复发相关,复发风险随抗体水平升高而增加。
临床怎么用
- CLIA可用于临床检测抗肾病蛋白IgG,辅助MCD/FSGS的疾病分层和纵向监测。
- 完全缓解期检测抗肾病蛋白IgG有助于识别3个月内复发高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Circulating anti-nephrin autoantibodies are being increasingly recognized in autoimmune podocytopathies, particularly minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). However, circulating anti-nephrin reactivity is often low, and currently available assays differ substantially in design, antigen production, and analytical performance. This methodological heterogeneity highlights the need for standardized and quantitative assays for clinical application. METHODS: Recombinant human nephrin ectodomain-coated magnetic microparticles were used to establish an automated chemiluminescence immunoassay (CLIA). Serum anti-nephrin IgG was measured in 121 children with biopsy-confirmed MCD (n=103) or primary FSGS (n=18), together with disease controls (genetically confirmed MCD/FSGS, IgA nephropathy, IgA vasculitis with nephritis, lupus nephritis, and ANCA-associated glomerulonephritis) and healthy individuals. Samples were tested in parallel by immunoprecipitation-Western blot (IP-WB). Antigen inhibition assays and cohort-based clinical analyses were performed. RESULTS: The CLIA met predefined analytical performance criteria and showed substantial agreement with IP-WB, with an overall concordance of 86.8% and Cohen's kappa coefficient of 0.714. CLIA detected anti-nephrin IgG more frequently than IP-WB in patients with MCD or FSGS (41.3% vs. 28.1%), including additional low-level positive samples. Antigen inhibition assays showed dose-dependent inhibition in CLIA-positive samples. Among patients with baseline nephrotic-range proteinuria, antibody positivity was associated with greater proteinuria, lower serum albumin, and steroid-sensitive nephrotic syndrome. Patients with elevated anti-nephrin IgG levels had significantly shorter relapse-free survival. During complete remission, anti-nephrin IgG positivity was associated with relapse within three months, with relapse risk increasing according to antibody level. CONCLUSIONS: Together, our automated CLIA may help move anti-nephrin IgG testing from specialized research workflows toward standardized clinical application, supporting future use in disease stratification and longitudinal monitoring.
引用
- Gu R, Zhang J, Qian C, et al. Automated chemiluminescence immunoassay for the detection of anti-nephrin autoantibodies. Kidney Int. 2026. PMID: 42767610. doi:10.1016/j.kint.2026.07.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。